Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. The company is headquartered in Canonsburg, Pennsylvania and currently employs 32,000 full-time employees. The firm's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. The company produces oral solid doses, injectables, and products with complex dosage forms.
Follow-Up Questions
Who is the CEO of Viatris Inc?
Mr. Scott Smith is the Chief Executive Officer of Viatris Inc, joining the firm since 2022.
What is the price performance of VTRS stock?
The current price of VTRS is $10.5, it has increased 0.14% in the last trading day.
What are the primary business themes or industries for Viatris Inc?
Viatris Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Viatris Inc market cap?
Viatris Inc's current market cap is $12.2B
Is Viatris Inc a buy, sell, or hold?
According to wall street analysts, 11 analysts have made analyst ratings for Viatris Inc, including 3 strong buy, 5 buy, 6 hold, 2 sell, and 3 strong sell
